{"status":"success","message":"The STAT_CONC_DEF field for indicator 3-d-2, translated into en","data":"<p>Percentage of bloodstream infection due to methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) and <em>Escherichia coli</em> resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. </p>\n<p> </p>\n<ul>\n  <li>Presumptive methicillin-resistant <em>S. aureus</em> (MRSA) isolates as defined by oxacillin minimum inhibitory concentration (MIC) and cefoxitin disc diffusion tests according to current internationally recognized clinical breakpoints (e.g., EUCAST or CLSI)<sup><a href=\"#footnote-2\" id=\"footnote-ref-2\">[1]</a></sup> </li>\n  <li><em>E. coli</em> resistant to third generation cephalosporins: <em>E. coli</em> isolates that are resistant as defined by current internationally recognized clinical breakpoints for third generation cephalosporins (e.g., EUCAST or CLSI), specifically ceftriaxone or cefotaxime or ceftazidime. </li>\n</ul><div class=\"footnotes\"><div><sup class=\"footnote-number\" id=\"footnote-2\">1</sup><p> EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Version 2.0. 2017. Both for species identification and antimicrobial susceptibility testing (AST)</p><p>CLSI. M100 Performance Standards for Antimicrobial Susceptibility Testing. 29th ed2018 <a href=\"https://clsi.org/standards/products/microbiology/documents/m100/\">https://clsi.org/standards/products/microbiology/documents/m100/</a> <a href=\"#footnote-ref-2\">&#x2191;</a></p></div></div>"}